DeepHealth Unveils Next‑Generation Imaging Informatics and Clinical AI Solutions at RSNA 2025

At the DeepHealth — the AI‑powered health‑informatics arm of RadNet, Inc. (Nasdaq: RDNT) — the company revealed a significantly expanded portfolio at RSNA 2025, showcasing “next‑generation” imaging informatics and clinical AI solutions designed to modernize radiology and improve population health worldwide. The new and enhanced offerings span the full imaging pipeline: disease detection, assessment and monitoring; remote scanning; image management and interpretation; center operations; and AI orchestration. At the heart of the revamp is the cloud-native DeepHealth OS — a unified platform that merges clinical and operational intelligence, streamlining workflows for radiologists, technologists, and administrators. Key components of the updated suite were introduced: Diagnostic Suite™ — Provides enterprise‑scale image management and interpretation with hybrid cloud/hybrid‑data management, ultra‑fast streaming viewers, AI‑powered automated reports, advanced visualization, and enterprise-level AI orchestration. With the acquisition of CIMAR UK, DeepHealth broadens cloud image‑management and cross‑region interoperability — supporting deployments across the UK and Europe, in addition to existing RadNet and teleradiology sites. TechLive™ — A vendor‑agnostic, multimodal remote imaging and radiology management solution (MR, CT, PET/CT, Ultrasound). Already cleared under FDA 510(k), TechLive enables centralized oversight of imaging procedures, helping expand access to advanced imaging in areas with workforce gaps. DeepHealth reports more than 400 connected scanners and a 42% reduction in MRI room closures, which leads to increased throughput and improved experiences for patients and technologists. Operations Suite™ — A comprehensive, cloud‑first operations toolset that unifies scheduling, registration, billing, analytics, and patient communication, also adding “agentic AI” features to reduce administrative burden, optimize throughput, and improve coordination across imaging centers. Existing users of legacy RIS (eRAD RIS) have the option to migrate to this enhanced platform. On the clinical‑AI front — under the “Population Health & Clinical AI” umbrella — DeepHealth expands and upgrades multiple specialty‑specific AI suites, many already cleared by the FDA or in advanced stages: Breast Suite: A modular, interoperable, end‑to‑end AI system for breast‑cancer detection, risk assessment, density evaluation, and diagnostic workflow tools. The Suite — enhanced by DeepHealth’s acquisition of iCAD — supports more than 10 million mammograms globally per year. Real‑world data published in 2025 (covering over 579,000 women) consistently show a 21% increase in breast‑cancer detection rate using the AI‑driven workflow — with improvements across dense-breast and diverse populations. Thyroid Suite: Integrates AI‑powered ultrasound workflows for thyroid imaging — automating measurement and characterization of thyroid nodules, standardizing reporting, and significantly boosting workflow efficiency. Built on technology from See‑Mode, the suite is deployable across all ultrasound vendors, standalone or in partnership with external manufacturers like GE HealthCare. In over 4,070 nodules assessed, radiologists accepted AI‑generated measurements without corrections in more than 94% of cases. Neuro Suite: Automates and standardizes neuroimaging analysis. Its AI tools — including “Brain Health” for white‑matter hyperintensity detection, and “Brain Age” for volumetric measurements of brain structures (hippocampus, lobes, subcortical regions) — facilitate longitudinal tracking of structural changes, aiming to support early intervention and proactive care. Chest Suite: Formerly “DeepHealth Lung,” this AI toolset automates pulmonary nodule detection, characterization, volumetric quantification, and longitudinal tracking — supporting early-stage lung-cancer screening programs. While cleared in Europe/UK, US regulatory approval is pending. Globally, the suite has already contributed to early detection programs. Prostate Suite: Designed for prostate MRI interpretation, automated lesion detection, risk classification, gland segmentation with PSA density calculation, plus PI‑RADS–compliant reporting and seamless integration with 9+ fusion biopsy systems. From scan review through biopsy planning, the suite aims to eliminate manual data transfer and standardize diagnostic workflows. Its latest version is slated to support screening trials in the UK and U.S. deployments. Supporting all these is AI Studio, a platform developed in collaboration with partners like CARPL.ai and RagaAI, which enables orchestration of over 140 AI algorithms from more than 75 external vendors — plus DeepHealth’s in-house clinical AI — directly within radiology workflows. AI Studio also provides tools for governance, performance monitoring, and drift management to ensure safe, scalable deployment. According to DeepHealth, its technologies are already used by thousands of imaging centers worldwide — more than 2,000 customers and over 5,000 radiologists — helping drive earlier, more accurate, and efficient disease detection, and enabling large-scale screening programs in breast, lung, prostate, neuro, and thyroid health. The company’s RSNA 2025 showcase includes live demonstrations, hands-on Experience Theater sessions, and panel discussions with clinical collaborators, research leaders, and technology partners — offering attendees a first look at how AI is being integrated into real-world radiology practices across clinical and operational domains. #DeepHealth #AIinRadiology #MedicalImaging #RSNA2025 #SlimScan #GrowthStocks #CANSLIM